My 5 best UK pharma stocks. I’d buy now to get rich in 10 years

The best UK pharma stocks to buy now could make investors rich, Tom Rodgers feels. He picks what he sees as the best from the FTSE 100 to AIM.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When I think about the best UK pharma stocks that could help me get rich over the next decade, this crop of the finest FTSE 100, FTSE 250 and AIM-listed shares come to mind.

To me these are the best UK pharma stocks because of their unimpeachable economic moats. This is the metric for greatness favoured by the world’s most successful investor Warren Buffett.

These companies achieve this feat through registered trademarks, copyrights and branded products that no other business can legally sell.

So despite high R&D costs, they remain at a long-term advantage to other industries.

Best UK pharma stocks: FTSE 100

GlaxoSmithKline (LSE:GSK) is a world leader in oncology (cancer treatments), HIV and respiratory drugs. And the business is expanding in personal care too. Extending its booming oral health business in India is positive news.

CEO Emma Walmsley declares the pharma giant’s 19p per share dividend like clockwork every quarter. It looks bombproof to me. When the Covid crisis forced FTSE 100 powerhouses like Royal Dutch Shell to cut their dividends, GSK powered on like nothing had happened.

The GSK dividend is 6%, nearly three times larger than the average healthcare stock, on a cheap P/E ratio of 10.

And with annual free cash flow of £5.1bn, there is plenty in the bank to keeping paying out year after year. That makes it a no-brainer buy for me.

My FTSE 250 pick

High-margin prescription veterinary drugs specialist Dechra Pharmaceuticals has me very interested. In the main, its speedy profit growth looks sustainable and the share price has just beaten recent all-time highs too.

Income payouts to Dechra investors are 89% higher than four years ago. And the business raised its dividend again after bumper 2020 full-year profits, which bodes well for the future.

Now for AIM

On AIM, truly great businesses are hard to find, even with the best UK pharma stocks. But picking wisely offers serious multibag possibilities. Novacyt remains a solid choice for me, and seeing its revenues grow 10 times larger year-on-year is of serious interest.

North Carolina-based Polarean Imaging has an unimpeachable economic moat with zero competitors for its non-invasive medical imaging tech. So I’m a fan. But the best UK pharma stock I’m backing to get rich over the next decade is one I already own — Open Orphan (LSE:ORPH).

I’m a huge fan of executive chairman Cathal Friel for stripping out costs and pushing the most profitable parts of the business forward since the 2019 IPO. And he has delivered on every promise to investors to date, lifting revenues with multi-million pound contracts.

Open Orphan has just signed a contract worth up to £40m with the UK government to provide human challenge tests for Covid-19. Clearly these kinds of revenues will be transformational for the small Anglo-Irish contract research business.

And there are a number of other strands of the business that have me excited. One of which is Open Orphan’s 49% ownership of Imutex, a joint venture with London drug manufacturer SEEK Group, which has a candidate for a universal flu vaccine, the holy grail of modern medicine.

The best thing I can say about Open Orphan is that 90% of its revenues have nothing to do with Covid-19. So I can predict it should continue to earn big money well into the future.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

TomRodgers has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »